Frederick Frank

Biography

Frederick Frank is Chairman of EVOLUTION Life Sciences Partners (ELSP). He is also co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm. Before joining ELSP, Mr. Frank was Chairman of Burrill Securities and Vice Chairman of Burrill & Company.He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and Director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman, Mr. Frank provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries, and was involved in hundreds of financings, strategic alliances, and merger and acquisition transactions in the global healthcare industry. Mr. Frank’s clients have included Marion Laboratories, from leading the company’s initial public offering to its acquisition of the pharmaceutical division of Dow Chemical, creating Marion Merrill Dow. Then, with Ms. Tanner, he represented Marion Merrill Dow in creating its merger with Hoescht to form Hoescht Marion Roussel, Inc. Mr. Frank also represented Synthelabo in France in its acquisition by Sanofi, which created the second largest French pharmaceutical company. Most recently, Mr. Frank advised CV Therapeutics Inc. in its $l.4B sale to Gilead Sciences Inc.; BioDuro LLC, a China-based company in its sale to PPD, Inc.; TargeGen, Inc., in its sale to sanofi-aventis; CGI Pharmaceuticals, Inc. in its sale to Gilead Sciences, Inc.; and OSI Pharmaceuticals Inc. in its sale to Astellas Pharma Inc.

Research Interest

pharmaceutical